Hemispherx’s Ampligen Needs Another Study, FDA Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Arthritis Advisory Committee recommends against approval of rintatolimod for chronic fatigue syndrome, saying that signs of efficacy seen in post-hoc analyses warrant further, prospective exploration in a new study before approval.